Detalles de la búsqueda
1.
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Am J Kidney Dis;
79(6): 796-806, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752913
2.
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Kidney Int;
99(3): 750-762, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33181154
3.
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
Nephrol Dial Transplant;
35(12): 2103-2111, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31495881
4.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab;
22(12): 2335-2347, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744354
5.
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
Kidney Int;
96(2): 489-504, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142441
6.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
J Am Soc Nephrol;
29(11): 2755-2769, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30314978
7.
Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
Circulation;
144(15): 1265-1267, 2021 10 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397263
8.
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Diabetes Obes Metab;
19(11): 1610-1619, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28636754
9.
The authors reply.
Kidney Int;
97(1): 213-214, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31901342
10.
Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
Kidney Int;
97(4): 631-635, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32200854
11.
Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Am J Kidney Dis;
74(5): 713-715, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31255334
12.
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.
EClinicalMedicine;
43: 101240, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35005582
13.
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
J Am Heart Assoc;
10(7): e020053, 2021 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33754809
14.
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.
Clin J Am Soc Nephrol;
15(10): 1433-1444, 2020 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32994159
15.
Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
J Am Heart Assoc;
9(18): e016976, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893717
16.
Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease.
Front Physiol;
11: 518, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32581831
17.
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.
J Diabetes Investig;
10(3): 760-770, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412655
18.
Neurovascular Response to Pressure in Patients With Diabetic Foot Ulcer.
Diabetes;
68(4): 832-836, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30679184
19.
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.
J Hypertens;
37(6): 1294-1300, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30540657
20.
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Circ Heart Fail;
12(6): e005875, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31163986